Company intelligence / Profile preview

Sanyo

Japan

Ownership: Private
Development stage: Other

Overview

Sanyo Fine provides active pharmaceutical ingredients (APIs) and regulatory services to the global pharmaceutical industry, with established expertise in organic and biochemical synthesis, now enhanced by integration with OSAKA SODA and FOOD & BIO RESEARCH CENTER, focusing on sugar chain-related technologies and custom services across drug development and commercial supply

Modalities: Small moleculeBiologic (via API synthesis)Peptides (for APIs if relevant)Custom organic synthesis
Industry: Contract Manufacturing Organization

Partnerships

Integration with OSAKA SODAmerger with FOOD & BIO RESEARCH CENTER

Beyond the preview

Go deeper on Sanyo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanyo.

Explore the full profile